Drug Evaluation Committee Current Status of RPA Introduction into PV Operations and Points to Keep in Mind
Pharmacovigilance Subcommittee
February 2022
With the recent promotion of digital transformation, RPA (Robotic Process Automation) has been introduced to the pharmaceutical industry and the field of pharmacovigilance. In December 2020, Task Force 2 of the Pharmacovigilance Subcommittee of the Drug Evaluation Committee of the Japan Pharmaceutical Manufacturers Association conducted a survey to ascertain the status of RPA adoption and challenges in the pharmaceutical industry in Japan. Based on the results of the questionnaire, we have compiled a list of RPA implementation systems, effects, and issues, and prepared this document to further promote the introduction of RPA. We hope that this document will be of assistance in the development of RPA, as it provides information on the status of RPA use by pharmaceutical companies and the challenges they face in promoting RPA development.
Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee
PV Subcommittee Task Force 2
Current Status and Points to Consider in Introducing RPA into PV Operations (1.21MB)